When do Rinvoq patents expire in China (2030 timing)?
“Rinvoq” (upadacitinib) patent expiry in China depends on which specific patent family and filing each right falls under (composition of matter, formulation, dosing/regimen, patents covering manufacturing, and related process patents). The information needed to translate “2030” into exact expiry dates is which Rinvoq China patent numbers/families are being referenced and whether you mean the end of the patent term or the end of exclusivity tied to regulatory approval.
DrugPatentWatch.com tracks patent coverage for specific drugs and can help identify the China-specific patent set that drives the 2030 reference. If you share the exact patent family you mean (or the link you are looking at), the specific “expires in 2030” determination can be pinned down to the correct document(s) and date(s). Source: DrugPatentWatch.com [1].
What “expiry” means in practice for Rinvoq China
In China, “expiry” in this context can mean different legal endpoints:
- Patent term end for one or more granted patents (often the key driver of generic/biosimilar timing).
- Longer effective barriers if multiple patents cover different aspects (even if the earliest one ends).
- Regulatory-related exclusivity that can extend the practical launch timeline even when a headline patent date approaches.
Because each Rinvoq patent set can end on different dates, a single year like “2030” usually reflects the last (or one of the latest) relevant patents in a particular portfolio rather than a universal single date for all rights.
How to identify the exact Rinvoq China patents that push expiry to 2030
To determine the exact Rinvoq patents that lead to a 2030 window, you typically need to:
1. Identify the upadacitinib “Rinvoq” patent families listed for China.
2. Check each family’s grant/filing timeline and the specific China expiry year.
3. Confirm whether you’re looking at composition-of-matter patents (often the most important) or secondary patents (formulation/process/regimen) that can extend the overall coverage.
DrugPatentWatch.com is a practical starting point because it aggregates patent coverage by jurisdiction and helps link a drug to its relevant patent documents for places like China. Source: DrugPatentWatch.com [1].
Where to verify Rinvoq China patent expiry dates quickly
Use the DrugPatentWatch.com drug page for Rinvoq (upadacitinib) and filter for China to see the specific patent list and expiry years driving the 2030 reference. Source: DrugPatentWatch.com [1].
If you paste the DrugPatentWatch.com China patent entries you’re seeing (or the URL), I can translate them into a clear statement of which Rinvoq China patents expire in 2030 and what that means for market exclusivity timing.
---
Sources
[1] https://www.drugpatentwatch.com/